R E Kessler
Bristol-Myers Squibb
33 Papers
557 Citations
R E Kessler is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Cefepime & Ceftazidime. The author has an hindex of 18, co-authored 33 publications.
Chat about Author
Papers
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
Daniel Bouzard,P. Di Cesare,M. Essiz,J. P. Jacquet,B. Ledoussal,P. Remuzon,R E Kessler,Joan Fung-Tomc +7 more
TL;DR: A (3S)-3-amino-pyrrolidine was shown to enhance greatly the in vitro and in vivo activity of the 5-methyl derivative, and was selected as a promising candidate for an improved therapeutic agent.
87
Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
TL;DR: Cefepime was active against most gram-negative bacteria which have developed resistance to the broad-spectrum cephalosporins, and resistance to cefEPime in P. aeruginosa appears to be associated with higher beta-lactamase levels than in cefepim-susceptible strains.
74
Identification and characterization of cell wall-cell division gene clusters in pathogenic gram-positive cocci.
TL;DR: Clusters of peptidoglycan biosynthesis and cell division genes (DCW genes) were identified and sequenced in two gram-positive cocci, Staphylococcus aureus and Enterococcus faecalis and indicated some similarities in organization compared with previously reported bacterial DCW gene clusters.
65
BMY 28100, a new oral cephalosporin.
F. Leitner,T. A. Pursiano,R. E. Buck,Y H Tsai,D R Chisholm,M. Misiek,J V Desiderio,R E Kessler +7 more
TL;DR: BMY 28100, a new oral cephalosporin with a (Z)-propenyl side chain at the 3 position and a p-hydroxyphenylglycyl substituent at the 7 position, was evaluated in comparison with cefaclor and cephalexin and, when appropriate, ampicillin and vancomycin.
64
In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.
TL;DR: Results indicate that BMS-181184 has a broad antifungal spectrum and that it is fungicidal to yeasts and, to a lesser extent, to filamentous fungi.
47